Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


MGI Pharma Inc.

Division of Eisai Co. Ltd.

Latest From MGI Pharma Inc.

Eisai Offloads AkaRx To Tighten Therapeutic Focus

Eisai is divesting its AkaRx operation and assets, acquired in 2010, to a health care-focused US private equity group in a move the Japanese firm says will free up resources for its two main therapeutic areas.

BioPharmaceutical Japan

Helsinn’s Family-Business Approach Goes Global In Cancer Care

Privately-owned Swiss firm preparing for its first solo launch in the US by doubling its sales force.

BioPharmaceutical Switzerland

Drais In Third Deal With Astellas, Seeks To Expand Partnership Model

Astellas has returned for a third time to enlist the development services of Drais, out-licensing a nocturia candidate which Drais will house in a virtual development company, Tacurion. Drais’ challenge now is to expand its portfolio of single-asset companies and its roster of investors.

Deals Strategy

Panel: Oncology Business Models Determined By Capital And Culture

Panelists with a variety of strategic motives met to discuss the pros and cons of business models at the Cancer Progress Meeting in New York City. The group represented both new and old firms, including some that perform research and some that license drugs.

BioPharmaceutical Business Strategies
See All

Company Information